Several of the most prevalent sexually transmitted infections are chronic subclinical inflammatory agents operating on the exact same biological pathways that serious longevity protocols are designed to address. They elevate IL-6, a protein the body produces during inflammation that, when chronically elevated, is independently linked to cardiovascular disease, neurodegeneration, and accelerated cellular aging. They drive TNF-alpha, another inflammatory signal tied to tissue damage and earlier death.
First, Let’s Establish Something: Sex Is Good for You
Before getting into infections and inflammatory biology, it is worth being direct about something the longevity data actually shows. Sex is not a risk to be managed around. It is a biological input that independently predicts better health outcomes and longer life, and treating it as anything less misses the point entirely.
Low testosterone in men is independently associated with increased visceral fat, insulin resistance, and all-cause mortality (Khaw et al., Circulation, 2007). Sexual frequency is inversely associated with fatal cardiovascular events, based on a 20-year follow-up study of over 2,300 men (Hall et al., American Journal of Cardiology, 2010). Intimate connection produces hormonal profiles, elevated oxytocin and reduced cortisol reactivity, that directly suppress inflammatory signaling. A meta-analysis covering 148 studies and more than 300,000 participants found that social isolation carries an all-cause mortality risk comparable to smoking 15 cigarettes per day (Holt-Lunstad et al., PLOS Medicine, 2010).
Bryan Johnson, a tech entrepreneur who has spent over $4 million building what he describes as the world’s most rigorous personal health protocol, understands this and is famously unshy about it. He tracks his own sexual function as an explicit cardiovascular and endothelial health proxy and has publicly reported nighttime erection results to be equivalent to that of a 20-year-old (or better!) His Blueprint health platform launched with low-dose daily tadalafil, a medication best known for treating erectile dysfunction but increasingly studied for its cardioprotective and vascular benefits, as a core longevity prescription. Sexual vitality is not adjacent to Bryan Johnson’s longevity protocol. It is inside it.
The same rigor the longevity community already applies to every other biological input should apply to sexual health. Right now, for most people running serious health protocols, it does not.
Sexual Health and Longevity is not as Straightforward as Other “Risky Behaviors”
Cigarettes make for a clean argument. There is no health upside. The damage accumulates from the first one, and no researcher has ever published data suggesting that smoking occasionally has benefits worth weighing against the risks.
Sex is categorically different, and the longevity conversation around it has to account for that honestly. It is biologically beneficial, emotionally meaningful, associated with reduced mortality, and a genuine component of a high-quality life. The risk profile that comes with sexual activity is real, but so is the reward profile, and any serious analysis has to hold both.
Bryan Johnson has described his broader health philosophy at the Lifespan Research Institute: “The entirety of our existence is the collection of all of our behaviors. By your decision not to go to bed on time, not to exercise, you’re basically stamping with approval everything that’s going on today.”
The solution to the tension between sexual health risks and sexual health benefits is not abstinence, it is information. Knowing one’s sexual health status on a regular cadence means that infections, which are often completely asymptomatic, get identified and treated before they operate silently on the body’s inflammatory environment for months or years. The goal is to protect the activity, not eliminate it.
What STIs Are Actually Doing to the Biology
There is a concept in aging science called “inflammaging.” It describes the chronic, low-level inflammatory state that accumulates as the body ages and quietly degrades nearly every major system. Cardiovascular disease, Alzheimer’s, metabolic dysfunction, and cancer all share this upstream driver (Franceschi et al., Nature Medicine, 2019). Managing it is the central preoccupation of serious longevity science. What has not been fully mapped is that several common STIs feed it directly.
Herpes
HSV-2, the virus that causes genital herpes, affects roughly 1 in 6 adults worldwide.
Most of them, around 87% by the data in JAMA (Tronstein et al., 2011), have no recognizable symptoms. No sores, no discomfort, no signal that anything is happening. The virus is not dormant though. HSV-2 establishes lifelong latency in a cluster of nerve tissue near the base of the spine and cycles through periodic reactivation events, each one triggering a release of IL-6, TNF-alpha, and other inflammatory proteins (Hu et al., Frontiers in Immunology, 2022). A recurring subclinical reactivation generates those inflammatory signals without producing a single noticeable symptom in the person carrying it.
There is also a neurological dimension that deserves more attention than it gets. HSV-1 and HSV-2 have both been linked to accelerated Alzheimer’s development through processes involving protein buildup and brain inflammation, with infection typically occurring years or decades before any cognitive symptoms appear (Zhang et al., Frontiers in Aging Neuroscience, 2023). This is not a skin condition with occasional inconvenient flare-ups. It is a chronic infectious process with long-horizon consequences for the brain and cardiovascular system.
While there is no cure, antiviral medications like valacyclovir significantly reduce both the frequency of reactivation events and the associated inflammatory load, meaning early detection directly translates to less cumulative biological damage over time. Knowing the status is the first step to managing it.
Chlamydia
Chlamydia, one of the most common bacterial infections in the world, generates an estimated 128 million new infections per year globally (WHO, 2020).
Approximately 70% of infected women and a substantial proportion of infected men have no symptoms. It can persist for months to years with no indication it is present, during which the immune system runs continuously in the background, driving sustained elevation of the same inflammatory proteins at the core of accelerated aging.
A landmark 1988 paper in The Lancet linked chlamydial infection to chronic coronary heart disease and acute myocardial infarction (Saikku et al., 1988), a finding that generated decades of follow-up research into bacterial infection as a direct cardiovascular risk driver.
The good news is that chlamydia is one of the most straightforwardly curable infections in existence. A single course of antibiotics, typically azithromycin or doxycycline, clears it completely in most cases. The entire inflammatory burden it was generating stops. The damage it was quietly accumulating stops with it. The only thing standing between an undetected chlamydial infection and a treated one is a test.
Syphilis
Syphilis, a bacterial infection that most people associate with a different era of medicine, is very much back.
Cases in the United States rose 79% over five years, reaching approximately 207,000 in 2023 (CDC STI Surveillance Report, 2023). The latent stage, where the bacteria persist in the body without obvious signs, can last for decades while continuing to generate immune activation and, in advanced cases, causing direct damage to the aorta and surrounding cardiac tissue (Rac et al., Sexually Transmitted Diseases, 2020).
When it is caught, treatment is remarkably straightforward: a single course of penicillin or doxycycline resolves most cases, stops the inflammatory cascade entirely, and prevents the cardiovascular damage that latent infection would otherwise cause over decades. Early detection does not just resolve the infection. It eliminates a long-horizon cardiovascular risk in a single prescription.
Mycoplasma genitalium
Mycoplasma genitalium is the one most people have genuinely never heard of, which is part of the problem.
It is a sexually transmitted bacterium estimated to infect around 1 to 2% of the general population, with considerably higher rates among sexually active adults under 35 (Sonnenberg et al., Journal of Infectious Diseases, 2015). Like chlamydia, it is predominantly asymptomatic and can persist undetected for extended periods while driving chronic inflammation.
What makes it particularly relevant from a longevity standpoint is what happens when it goes undiagnosed for too long: Mycoplasma genitalium has developed significant antibiotic resistance, meaning late-stage infections are genuinely harder to treat than early ones (Jensen et al., Clinical Infectious Diseases, 2016).
This is the rare STI where delay actively narrows the treatment options available. Caught early, it responds well to a specific antibiotic combination, typically doxycycline followed by azithromycin or moxifloxacin, and clears completely. Caught late, after resistance has developed, treatment becomes a more complicated clinical problem that takes longer to resolve and is harder on the body.
The Mental Model Problem
Most people apply one heuristic to sexual health: no symptoms, no problem. It is an understandable default and a consistently unreliable one for exactly the infections that matter most. HSV-2’s near-87% asymptomatic rate is not a coincidence. It reflects thousands of years of co-evolution between viruses and their human hosts, in which viruses that produced dramatic symptoms got avoided and those that went unnoticed spread more successfully. Stealth is the evolutionary outcome, not an edge case.
The longevity community has already rejected subjective experience as an acceptable standard of evidence in every other domain. Nobody running a serious health protocol accepts “I feel fine” as a substitute for a blood panel or an inflammatory marker reading. Bryan Johnson has stated the underlying principle plainly: “Don’t trust human opinion. Trust data.”
Peter Attia, a physician and longevity researcher whose book Outlive brought the concept of proactive, upstream medicine to a mainstream audience, builds his entire clinical framework around one central idea: act on risk factors long before pathology declares itself through symptoms. He calls it Medicine 3.0. He would not advise waiting for a heart attack to start tracking cholesterol. An undetected STI driving subclinical inflammation for 18 months is exactly the kind of slow-moving, symptomless upstream threat that framework is designed to catch before it compounds.
David Sinclair, a Harvard geneticist and one of the most cited researchers in aging biology, has described how chronic immune activation accelerates epigenetic aging, the process by which the body’s cells accumulate damage and function as if they are older than they chronologically are (Lifespan, 2019). The source of that immune activation is biologically irrelevant to the process. A persistent infection produces the same downstream aging signal as poor sleep or a poor diet. The biology does not distinguish between sources.
The Problem With Standard STI Testing, and Why Home Testing Solves It
Standard STI testing at most clinics and primary care offices tests a single site: the genitals, via urine. That sounds thorough until you look at where infections actually live. A study examining 45 million gonorrhea and chlamydia tests in the United States found that only 1.5% of women received a throat swab and only 0.4% received an anal swab, despite oral and rectal infections being common and frequently asymptomatic (Danville et al., Sexually Transmitted Diseases, 2023). The positivity rates at those non-genital sites are not trivial: rectal chlamydia runs at 7.3%, throat gonorrhea at 2.4%, rectal gonorrhea at 3.2%. The genitals showed the lowest positivity rate of the three sites tested.
That means millions of people walk out of a clinic every year with a negative result that does not reflect their actual status.
Self-collected home tests offer multi-site testing: a urine sample plus oral and rectal swabs, and catches what single-site genital testing systematically misses. For someone who has built their health philosophy around not accepting incomplete data, testing only genitally is the equivalent of running extensive bloodwork to track inflammation while ignoring one of its most common sources.
The format also fits naturally with how serious longevity protocols already operate. Tests ordered from home, samples self-collected, results returned quickly and directly. No waiting room, no appointment, no friction between the person and their health data. A comprehensive self-collected STI panel with 24 to 72 hour turnaround integrates into an existing health stack without disrupting it.
As Bryan Johnson has put it when describing his broader Blueprint mission: “I don’t think you can win by changing the healthcare system. You have to build over it.” A testing model that is more comprehensive than what most clinicians offer, available without a clinic visit, is exactly that architecture in practice.
What a Routine Protocol Actually Looks Like
For someone in a stable, exclusive partnership where both partners have clear recent test results: an annual comprehensive STI panel, folded into existing blood work. Chlamydia and gonorrhea via PCR, syphilis via blood test, HIV via 4th generation antibody test, hepatitis B and C via blood spot card, HSV-1 and HSV-2 via antibody serology, and mycoplasma genitalium via PCR. One panel, once a year, minimal friction.
For someone with new or multiple partners since their last test: every 60 to 90 days is the appropriate cadence, and testing before beginning unprotected sexual activity with a new partner closes the most significant risk window. HIV testing detects infection within 18 to 45 days with a modern 4th generation test. HSV antibody testing can take up to 12 weeks to confirm. The 60 to 90 day interval covers both.
On the biomarker side, unexplained elevation in hsCRP, a blood marker for systemic inflammation, above 1.0 mg/L in the absence of other explanatory factors is worth investigating, and sexual health history belongs in that review. An elevated neutrophil-to-lymphocyte ratio, another general inflammatory flag available through standard blood work, is worth the same attention. Neither is specific to STIs. Both signal that something in the inflammatory environment is active, and infectious exposure is a rational part of the differential that most longevity-focused people are not currently running.
Closing the Loop
The inflammation that serious longevity protocols work hardest to suppress can be continuously re-fed by an infection that produces no symptoms, shows up on no routine panel, and gets detected only when someone decides to look for it.
Sexual health and longevity connect through the same cytokine pathways, the same endothelial biology, the same epigenetic mechanisms that the rest of a serious protocol already addresses. The data exists. The testing exists. Adding a regular cadence of comprehensive, multi-site, self-collected STI testing to an existing longevity protocol requires minimal effort and closes a real gap in the biological picture.
And in a framework where the entire point is that what you don’t measure cannot be managed, leaving it unmeasured is the choice that contradicts everything else.
Close the loop.
This article is for informational and educational purposes only and does not constitute medical advice. Readers should consult a licensed healthcare provider for testing and treatment decisions.
